Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide does not produce instant results — the medicine starts acting on your body from the first dose, but noticeable weight loss usually takes several weeks to build. Most people begin to feel reduced appetite within the first week or two, while meaningful changes on the scales typically emerge over months, not days. That distinction matters when you're setting expectations. Tirzepatide (sold in the UK as Mounjaro) is a prescription-only medicine, which means a clinician assesses your full health picture before it's prescribed — and part of that conversation is exactly this: what a realistic timeline looks like for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception people bring to tirzepatide is that the scales should shift within the first week or two. They don't, and expecting them to can lead to real disappointment, or worse, abandoning a treatment that simply needed more time.
Here's what's actually happening in those early weeks. The body is adjusting to a new hormonal signal. Tirzepatide activates both GIP and GLP-1 receptors, which influence appetite, gastric emptying, and the way the body handles energy, a process explained in more detail on our page about how tirzepatide works. That adjustment doesn't produce a sudden drop on the scales. What it produces, for many people, is a quieter appetite: food feels less urgent, portions feel more satisfying, and the background noise of hunger starts to fade.
That shift in appetite is the mechanism through which weight loss eventually follows. But the weight comes off because of a sustained calorie deficit over time, not because of an acute pharmacological event on day one. Think of the first month less as a treatment phase and more as an acclimatisation phase, the body learning a new normal.
If you want a closer look at how tirzepatide's dual-receptor activity actually drives these changes, our page on how GIP works in tirzepatide walks through the science without the jargon.
The SURMOUNT-1 trial (published in the New England Journal of Medicine) followed adults with obesity over 72 weeks. Average weight loss at the highest dose reached around 20–21% of starting body weight. That is a large number. But it arrived over nearly a year and a half, not a fortnight.
Early trial data suggest participants began to separate from the placebo group within the first four to eight weeks, but the curve is gradual. Weight loss tends to accelerate as doses increase through the prescriber-guided schedule, starting at 2.5mg and moving up in steps. The starter dose's job is to settle the gastrointestinal system, nausea, the most common early side effect, is far less likely when the body is introduced to the medicine slowly. Therapeutic weight loss becomes more pronounced at higher maintenance doses.
This is worth knowing before you start, because the first pen can feel anticlimactic. That's entirely normal. Our page on how long tirzepatide takes to work covers the dose-by-dose progression in more detail.
The NHS patient information for tirzepatide confirms this graduated approach and sets out what to expect at each stage of treatment, worth reading before your first injection.
We hear a version of this question from a lot of people starting out: 'How will I know if it's doing anything?' It's a fair thing to wonder, particularly when the scales aren't yet moving.
The earliest sign that tirzepatide is working is usually a change in appetite rather than a change in weight. Food becomes less preoccupying. Cravings quieten. Some people find they leave food on the plate without thinking about it, something that felt impossible before. These are the early signals that the medicine is doing its job, even before the numbers shift.
Weight loss typically becomes measurable after four to eight weeks, and more consistent after three months. Progress is rarely linear: there are weeks where nothing changes and then a noticeable drop. This is normal and reflects water retention, hormonal fluctuation, and the body's natural adjustment patterns, not a sign the medicine has stopped working.
For a side-by-side look at how Mounjaro compares with other weight-loss medicines on timeline and average outcomes, our weight-loss treatment overview is a useful starting point. And if you're wondering whether the early experience differs between the injection and other formats, our tirzepatide overview brings together the key facts in one place.
One practical note: the NHS tirzepatide medicines page includes guidance on what to do if you feel you're not responding as expected, always worth reading alongside your prescriber's advice rather than adjusting anything yourself.
Two people starting tirzepatide on the same day, at the same dose, can have noticeably different experiences in the first three months. That's not a flaw in the medicine, it's a reflection of biology.
Starting weight plays a role: someone with more weight to lose may see larger absolute numbers early on, even if the percentage change is similar. Diet matters considerably, tirzepatide reduces appetite but works best alongside a genuinely lower-calorie intake, and people who adjust their eating patterns alongside treatment tend to see faster progress. Physical activity contributes, particularly in preserving lean muscle as weight comes off, which in turn supports continued fat loss. And dose matters: the medicine's effects strengthen as titration progresses, so the pace of weight loss often picks up in months three to six as doses increase.
None of these factors can be optimised in isolation, which is why a clinical review at every step is built into how tirzepatide is prescribed responsibly. If you're at the point of thinking seriously about starting, how Mounjaro is accessed in the UK explains the prescription process. When you're ready to speak to a prescriber, our team at weight-loss treatments offers a free consultation, a real clinician reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.